Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of filgotinib in psoriatic arthritis
2017-000545-52Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgotinib in psoriatic arthritis (PsA), sponsored by Galapagos NV. Primary endpoint: Safety and tolerability over time. Started Jun 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2017-000545-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000545-52.